This article is available to subscribers. Subscribe now. Already have an account? Sign in

Clinical Implications of Basic ResearchFree Preview

The Potency of a KRAS Silent Variant

List of authors.
  • Miriam Molina-Arcas, Ph.D.,
  • and Julian Downward, Ph.D.

The overrepresentation of a silent variant in KRAS led investigators to explore whether this mutation was biologically relevant (it was) and could be exploited in a mouse model to treat KRAS-mutant cancer.

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

Author Affiliations

From the Francis Crick Institute, London.

Print Subscriber? Activate your online access.